Media

There are very few things that are as synonymous with NYC as the yellow taxi cab, but like most things there are some DO’s and DON’TS when trying to catch a cab, so in this edition of the Urban Guidebook, our host Annamaria Chen takes on the Taxi. We’re not only showing you how to successfully hail a cab but we’re sharing our pro tips so you don’t get taken for a ride.

The NYC Urban Guidebook is a comedic video series which aims to help visitors better understand the in-and-outs of New York City. The series is currently streaming on the ClearVISION Network, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its TSA-approved QS-B220 explosives trace detector to The Delivery People for use in U.S. air cargo screening. The QS-B220 is the first explosives trace detector (ETD) system purchased by The Delivery People, a full service, asset-based transportation provider that is also a Certified Cargo Screening Facility (CCSF). Transportation and logistics companies with CCSF status are certified by the TSA to screen air cargo packages for explosives before they are loaded onto airplanes. CCSFs are required to use TSA-approved screening systems.

“The decision maker at The Delivery People was very familiar with ETDs. When compared with competing systems, based on a strong recommendation from a current customer, combined with the systems’ favorable ease of use and low total cost of ownership, they selected the QS-B220,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones. “Customer adoption rates for the QS-B220 have significantly increased over the past quarter and we look forward to continued sales momentum in the near future.”

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company’s QS-B220 has also received STAC certification and a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act).

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the Ohio State Innovation Foundation, an affiliate of The Ohio State University, for a novel oligonucleotide drug delivery platform, Lipid-Coated Albumin Nanoparticle (LCAN), developed at The Ohio State University College of Pharmacy. In preclinical studies, the LCAN platform has demonstrated the ability to deliver oligonucleotide compounds into cancer tumors, which can result in improved safety and efficacy. Rexahn’s first preclinical candidate to be developed with this delivery platform will be RX-0201-nano.

“The LCAN platform allows Rexahn to specifically target cancer tumors with oligonucleotides in a way that increases potency and reduces side effects, and is a broad platform that has the ability to generate multiple therapeutic candidates going forward. We will initially move forward with RX-0201-nano as the first candidate from the LCAN platform, and we anticipate entering the clinic with the first candidate within two years,” stated Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. “Furthermore, the platform also offers Rexahn the ability to use this delivery platform to enhance and create additional next generation oligonucleotide therapies.”

LCAN incorporates both cationic lipid and a cationized albumin that can form an electrostatic complex with oligonucleotides and be co-encapsulated by lipids. It also has a targeting moiety conjugated on the surface to direct the LCAN directly to the cancer tumors. RX-0201-nano is a nanoliposomal Akt1 inhibitor, similar to the Company’s Archexin® which may be effective in solid tumors and hematological malignancies and has shown high efficiency and good stability in preclinical studies.

Robert J. Lee, Ph.D., researcher at The Ohio State University College of Pharmacy and the inventor of the LCAN technology, commented, “The LCAN platform represents a significant advancement in targeted delivery of oligonucleotides to cancer tumors. Other types of formulation approaches have been tried in the past but none offered such potent activity for the targeted delivery of an oligonucleotide to the cancer tumor.”

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

About The Ohio State University College of Pharmacy

Established in 1885, The Ohio State University College of Pharmacy is a leader in pharmaceutical education, research and clinical practice. As part of one of the most comprehensive health sciences campuses in the nation, the college is home to world-class faculty, dedicated researchers and top students who are leading the way in pharmacy education, practice and research. The college’s graduate programs are currently ranked 7th in the nation by U.S. News & World Report.

About The Ohio State University:

Ohio State is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, The Ohio State University is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers, and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences, and the professions.

Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117

Implant Sciences Sells TSA-Approved Explosives Trace Detectors to R&M Trucking

New york has earned the reputation as one of America’s most haunted cities. Home to North America’s largest mass grave site and the former stomping grounds of some history’s creepiest characters and writers there is no shortage of ghost sightings and stories. Our host Annamaria Chen, meets up with Jamie Owens, a tour guide from Ghosts of New York Walking Tours, the cities oldest ghost tour company to check out some of these haunted places during the” Peter Stuyvesant and His Ghostly Friends of the East Village Tour.”

Home

The SpendSmart Payments Company & Justin Bieber Partner on “Cash for College”

Interview with Can-Fite BioPharma (CANFY) CEO Dr. Pnina Fishman